Evidence Hub

Non-coding RNAs in cardiovascular health and disease

R. Boon

Non-coding RNA Research, 2018

5 citations

Abstract

Cardiovascular disease is a worldwide epidemic. Even though new therapies are emerging, cardiac remodeling and subsequent heart failure remain critical issues after myocardial infarction with high rates of mortality. Because of the high death rate and the economic burden for society, researchers are exploring uncharted territory aiming to improve our understanding of the underlying processes of heart disease, with the ultimate goal to devise new strategies for therapeutic intervention. A previously unrecognized class of molecules, so called noncoding RNAs (ncRNA), is moving into the focus as valid therapeutic targets to tackle heart disease in (pre-)clinical settings [1]. With the advent of modern molecular biology techniques like next generation sequencing, it has become clear that the majority of the genome is transcribed into RNA, while only 2% of the transcribed genome encodes proteins. The transcribed portion of the genome that does not code for proteins is known as non-coding RNA. These noncoding RNAs include ribosomal RNAs, transfer RNAs, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). MiRNAs and lncRNAs are relatively recently discovered and play important roles in posttranscriptional and epigenetic gene expression regulation and are often expressed in a cell-type-specific manner [1]. In this special issue, several review papers cover recent advances in non-coding RNA research in the field of cardiovascular disease. Two publications provide an overview of…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free